In an interview with Pharm Exec deputy editor Don Tracy, Femasys founder and CEO Kathy Lee-Sepsick talks about the results of Femaseed’s pivotal trial, the Fembloc contraceptive pill, and how the outcome of the 2024 U.S. presidential election may impact women’s health.
Femasys CEO Discusses FemaSeed Pivotal Trial Results and the History of FemBlock Contraception
You Might Also Like
Leave a Comment
Latest News
Recent Posts
- Goldman launches three-year technology investment plan
- Wells Fargo is committed to risk infrastructure and efficiency initiatives
- Creative Engineering Under Pressure by Jesse Velez and Ben Eadie
- Chart: Global Retail CEOs’ Q4 2024 Outlook
- ABBANK in Vietnam announces SME digital banking platform powered by Backbase